secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001641172-25-014700
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma appoints new director, amends equity facility to raise up to $20M
------------------------------------------------------------------------------

- Andrew Ritter resigned from board effective June 9, 2025.
- David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.
- Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.
- Equity facility remains at $20M; change gives more flexibility for future stock sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer